TY - JOUR T1 - Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands JF - medRxiv DO - 10.1101/2020.08.21.20177857 SP - 2020.08.21.20177857 AU - Brenda M. Westerhuis AU - Erwin de Bruin AU - Felicity D. Chandler AU - Chris R. B. Ramakers AU - Nisreen M.A. Okba AU - Wentao Li AU - Herman Goossens AU - Menno D. de Jong AU - Berend Jan Bosch AU - Bart L. Haagmans AU - Pieter L. A. Fraaij AU - Reina S. Sikkema AU - Marion P.G. Koopmans Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/24/2020.08.21.20177857.abstract N2 - Understanding the coronavirus (CoV) antibody landscape in relation to disease and susceptibility is critical for modelling of steps in the next phase during the current covid-19 pandemic. In March 2020, during the first month of the epidemic in The Netherlands, we performed cross sectional studies at two time points amongst patients of the Erasmus Medical Centre in Rotterdam, to assess the presence of antibodies against seasonal human coronaviruses (OC43, 229E, NL63, HKU1), emerging zoonotic coronaviruses (SARS, MERS) and SARS-CoV-2 in nine different age groups. We observed minimal SARS-CoV-2 reactivity early March (0.7% of sera), increasing to 3.0%, four weeks later, suggesting probably undetected cases during this early phase of the epidemic. Antibody responses were mostly coronavirus species specific at young age, but possible cross-reactivity between human seasonal CoVs was observed with increasing age.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No. 874735 (VEO) and No. 101003589 (RECoVER)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ErasmusMC medical ethical board and informed consent was waived as data were collected anonymized (MEC-2020-0158).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. ER -